{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:49:05Z","timestamp":1792442945708,"version":"4.5.0"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"DOI":"10.1186\/s12969-025-01149-5","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T12:47:15Z","timestamp":1759754835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["New avenues in childhood vasculitis"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0138-8791","authenticated-orcid":false,"given":"Hulya","family":"Ercan Emreol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6257-7903","authenticated-orcid":false,"given":"Cagri","family":"Yildirim-Toruner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1728-4260","authenticated-orcid":false,"given":"Marija","family":"Jelusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1954-2822","authenticated-orcid":false,"given":"Marinka","family":"Twilt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2883-7868","authenticated-orcid":false,"given":"Seza","family":"Ozen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"1149_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.853724","volume":"10","author":"M Jelusic","year":"2022","unstructured":"Jelusic M, Sestan M, Giani T, Cimaz R. New insights and challenges associated with IgA vasculitis and IgA vasculitis with nephritis-is it time to change the paradigm of the most common systemic vasculitis in childhood?? Front Pediatr. 2022;10:853724. https:\/\/doi.org\/10.3389\/fped.2022.853724.","journal-title":"Front Pediatr"},{"key":"1149_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152209","volume":"61","author":"M Sestan","year":"2023","unstructured":"Sestan M, et al. Clinical features, treatment and outcome of pediatric patients with severe cutaneous manifestations in IgA vasculitis: multicenter international study. Semin Arthritis Rheum. 2023;61:152209. https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152209.","journal-title":"Semin Arthritis Rheum"},{"key":"1149_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/1759720x211024828","volume":"13","author":"M Sestan","year":"2021","unstructured":"Sestan M, et al. Gastrointestinal involvement and its association with the risk for nephritis in IgA vasculitis. Ther Adv Musculoskelet Dis. 2021;13:1759720x211024828. https:\/\/doi.org\/10.1177\/1759720x211024828.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1149_CR4","doi-asserted-by":"publisher","first-page":"912929","DOI":"10.3389\/fimmu.2022.912929","volume":"13","author":"XQ Chen","year":"2022","unstructured":"Chen XQ, Tu L, Tang Q, Huang L, Qin YH. An emerging role for neutrophil extracellular traps in IgA vasculitis: a mini-review. Front Immunol. 2022;13:912929. https:\/\/doi.org\/10.3389\/fimmu.2022.912929.","journal-title":"Front Immunol"},{"key":"1149_CR5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/s0272-6386(00)70192-2","volume":"35","author":"M Endo","year":"2000","unstructured":"Endo M, Ohi H, Ohsawa I, Fujita T, Matsushita M. Complement activation through the lectin pathway in patients with Henoch-Sch\u00f6nlein purpura nephritis. Am J Kidney Dis. 2000;35:401\u20137. https:\/\/doi.org\/10.1016\/s0272-6386(00)70192-2.","journal-title":"Am J Kidney Dis"},{"key":"1149_CR6","doi-asserted-by":"publisher","unstructured":"Nurmi MS, P\u00e9rez-Al\u00f3s L, Fellstr\u00f6m B, Garred P, Lundberg S. #887 complement biomarkers in IgA nephropathy and IgA vasculitis with renal involvement: can urine rather than blood be the answer? Nephrol Dialysis Transplantation. 2024;39. https:\/\/doi.org\/10.1093\/ndt\/gfae069.1241.","DOI":"10.1093\/ndt\/gfae069.1241"},{"key":"1149_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12040750","author":"S Srsen","year":"2024","unstructured":"Srsen S, et al. Serum levels of S100A8\/A9 as a biomarker of disease activity in patients with IgA vasculitis. Biomedicines. 2024. https:\/\/doi.org\/10.3390\/biomedicines12040750.","journal-title":"Biomedicines"},{"key":"1149_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s11306-024-02107-0","author":"A Boissais","year":"2024","unstructured":"Boissais A, et al. A specific diagnostic metabolome signature in adult IgA vasculitis. Metabolomics. 2024. https:\/\/doi.org\/10.1007\/s11306-024-02107-0.","journal-title":"Metabolomics"},{"key":"1149_CR9","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.semarthrit.2020.09.006","volume":"50","author":"S Demir","year":"2020","unstructured":"Demir S, et al. Predictive biomarkers of IgA vasculitis with nephritis by metabolomic analysis. Semin Arthritis Rheum. 2020;50:1238\u201344. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.09.006.","journal-title":"Semin Arthritis Rheum"},{"key":"1149_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042253","author":"G Laskarin","year":"2024","unstructured":"Laskarin G, et al. Involvement of M1-activated macrophages and perforin\/granulysin expressing lymphocytes in IgA vasculitis nephritis. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25042253.","journal-title":"Int J Mol Sci"},{"key":"1149_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10067-018-4250-8","volume":"38","author":"A Ho\u010devar","year":"2019","unstructured":"Ho\u010devar A, et al. Microrna expression in the affected skin of adult patients with IgA vasculitis. Clin Rheumatol. 2019;38:339\u201345. https:\/\/doi.org\/10.1007\/s10067-018-4250-8.","journal-title":"Clin Rheumatol"},{"key":"1149_CR12","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/ard.2009.116657","volume":"69","author":"S Ozen","year":"2010","unstructured":"Ozen S, et al. EULAR\/PRINTO\/PRES criteria for Henoch-Sch\u00f6nlein purpura, childhood polyarteritis nodosa, childhood wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis. 2010;69:798\u2013806. https:\/\/doi.org\/10.1136\/ard.2009.116657.","journal-title":"Ann Rheum Dis"},{"key":"1149_CR13","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1136\/annrheumdis-2020-218649","volume":"80","author":"M Sapina","year":"2021","unstructured":"Sapina M, et al. Geospatial clustering of childhood IgA vasculitis and IgA vasculitis-associated nephritis. Ann Rheum Dis. 2021;80:610\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218649.","journal-title":"Ann Rheum Dis"},{"key":"1149_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00467-024-06502-6","volume":"40","author":"M Vivarelli","year":"2025","unstructured":"Vivarelli M, et al. IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis. Pediatr Nephrol. 2025;40:533\u201369. https:\/\/doi.org\/10.1007\/s00467-024-06502-6.","journal-title":"Pediatr Nephrol"},{"key":"1149_CR15","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40620-022-01509-4","volume":"36","author":"N Kifer","year":"2023","unstructured":"Kifer N, et al. Semiquantitative classification (SQC) and Oxford classifications predict poor renal outcome better than the international study of kidney disease in children (ISKDC) and haas in patients with IgAV nephritis: a multicenter study. J Nephrol. 2023;36:441\u20139. https:\/\/doi.org\/10.1007\/s40620-022-01509-4.","journal-title":"J Nephrol"},{"key":"1149_CR16","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1007\/s00247-022-05399-3","volume":"52","author":"H Zhang","year":"2022","unstructured":"Zhang H, et al. Contrast-enhanced ultrasonography for assessing histopathology in pediatric Immunoglobulin A nephropathy and Henoch-Sch\u00f6nlein purpura nephritis. Pediatr Radiol. 2022;52:2575\u201383. https:\/\/doi.org\/10.1007\/s00247-022-05399-3.","journal-title":"Pediatr Radiol"},{"key":"1149_CR17","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1007\/s10067-023-06781-8","volume":"42","author":"CEC Williams","year":"2023","unstructured":"Williams CEC, Lamond M, Marro J, Chetwynd AJ, Oni L. A narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP). Clin Rheumatol. 2023;42:3189\u2013200. https:\/\/doi.org\/10.1007\/s10067-023-06781-8.","journal-title":"Clin Rheumatol"},{"key":"1149_CR18","doi-asserted-by":"publisher","first-page":"11510","DOI":"10.1038\/s41598-021-91055-z","volume":"11","author":"D Prieto-Pe\u00f1a","year":"2021","unstructured":"Prieto-Pe\u00f1a D, et al. BAFF, APRIL and BAFFR on the pathogenesis of immunoglobulin-A vasculitis. Sci Rep. 2021;11:11510. https:\/\/doi.org\/10.1038\/s41598-021-91055-z.","journal-title":"Sci Rep"},{"key":"1149_CR19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176938","author":"JC Burns","year":"2024","unstructured":"Burns JC. The etiologies of Kawasaki disease. J Clin Invest. 2024. https:\/\/doi.org\/10.1172\/JCI176938.","journal-title":"J Clin Invest"},{"key":"1149_CR20","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jpc.15816","volume":"58","author":"R Lucas","year":"2022","unstructured":"Lucas R, et al. Epidemiology of Kawasaki disease in Australia using two nationally complete datasets. J Paediatr Child Health. 2022;58:674\u201382. https:\/\/doi.org\/10.1111\/jpc.15816.","journal-title":"J Paediatr Child Health"},{"key":"1149_CR21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jpeds.2006.03.050","volume":"149","author":"K Egami","year":"2006","unstructured":"Egami K, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2006;149:237\u201340. https:\/\/doi.org\/10.1016\/j.jpeds.2006.03.050.","journal-title":"J Pediatr"},{"key":"1149_CR22","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011319","volume":"8","author":"MBF Son","year":"2019","unstructured":"Son MBF, et al. Risk model development and validation for prediction of coronary artery aneurysms in Kawasaki disease in a North American population. J Am Heart Assoc. 2019;8:e011319. https:\/\/doi.org\/10.1161\/JAHA.118.011319.","journal-title":"J Am Heart Assoc"},{"key":"1149_CR23","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1161\/CIRCULATIONAHA.105.592865","volume":"113","author":"T Kobayashi","year":"2006","unstructured":"Kobayashi T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113:2606\u201312. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.592865.","journal-title":"Circulation"},{"key":"1149_CR24","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-059175","author":"Y Kuniyoshi","year":"2023","unstructured":"Kuniyoshi Y, et al. Prediction models for intravenous immunoglobulin resistance in Kawasaki disease: a meta-analysis. Pediatrics. 2023. https:\/\/doi.org\/10.1542\/peds.2022-059175.","journal-title":"Pediatrics"},{"key":"1149_CR25","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1097\/00006454-200011000-00012","volume":"19","author":"DE Bronstein","year":"2000","unstructured":"Bronstein DE, et al. Relationship of climate, ethnicity and socioeconomic status to Kawasaki disease in San Diego county, 1994 through 1998. Pediatr Infect Dis J. 2000;19:1087\u201391. https:\/\/doi.org\/10.1097\/00006454-200011000-00012.","journal-title":"Pediatr Infect Dis J"},{"key":"1149_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jpeds.2019.05.024","volume":"212","author":"A Dionne","year":"2019","unstructured":"Dionne A, et al. Impact of socioeconomic status on outcomes of patients with Kawasaki disease. J Pediatr. 2019;212:87\u201392. https:\/\/doi.org\/10.1016\/j.jpeds.2019.05.024.","journal-title":"J Pediatr"},{"key":"1149_CR27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.cjcpc.2022.10.007","volume":"1","author":"JP Wong","year":"2022","unstructured":"Wong JP, et al. Socioeconomic status and Kawasaki disease outcomes in a single-payer health care system. CJC Pediatric and Congenital Heart Disease. 2022;1:248\u201352. https:\/\/doi.org\/10.1016\/j.cjcpc.2022.10.007.","journal-title":"CJC Pediatric and Congenital Heart Disease"},{"key":"1149_CR28","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-039933","author":"K Javalkar","year":"2021","unstructured":"Javalkar K, et al. Socioeconomic and racial and\/or ethnic disparities in multisystem inflammatory syndrome. Pediatrics. 2021. https:\/\/doi.org\/10.1542\/peds.2020-039933.","journal-title":"Pediatrics"},{"key":"1149_CR29","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1097\/INF.0b013e31817acf4f","volume":"27","author":"AS Kao","year":"2008","unstructured":"Kao AS, Getis A, Brodine S, Burns JC. Spatial and temporal clustering of Kawasaki syndrome cases. Pediatr Infect Dis J. 2008;27:981\u20135. https:\/\/doi.org\/10.1097\/INF.0b013e31817acf4f.","journal-title":"Pediatr Infect Dis J"},{"key":"1149_CR30","first-page":"104","volume":"79","author":"TJ Dawson","year":"2020","unstructured":"Dawson TJ, et al. Mapping the trends of Kawasaki disease in hawai\u2019i from 1996 to 2018. Hawaii J Health Soc Welf. 2020;79:104\u201311.","journal-title":"Hawaii J Health Soc Welf"},{"key":"1149_CR31","doi-asserted-by":"publisher","first-page":"1054985","DOI":"10.3389\/fped.2022.1054985","volume":"10","author":"J Kim","year":"2022","unstructured":"Kim J, Hong K, Yoo D, Chun BC. Spatiotemporal clusters of Kawasaki disease in South Korea from 2008 to 2017: A municipal-level ecological study. Front Pediatr. 2022;10:1054985. https:\/\/doi.org\/10.3389\/fped.2022.1054985.","journal-title":"Front Pediatr"},{"key":"1149_CR32","doi-asserted-by":"publisher","first-page":"22584","DOI":"10.1038\/s41598-021-01961-5","volume":"11","author":"JA Burney","year":"2021","unstructured":"Burney JA, et al. Temporal clustering of Kawasaki disease cases around the world. Sci Rep. 2021;11:22584. https:\/\/doi.org\/10.1038\/s41598-021-01961-5.","journal-title":"Sci Rep"},{"key":"1149_CR33","doi-asserted-by":"publisher","first-page":"e1165","DOI":"10.1161\/CIR.0000000000001234","volume":"149","author":"JP Zachariah","year":"2024","unstructured":"Zachariah JP, et al. Environmental exposures and pediatric cardiology: a scientific statement from the American Heart Association. Circulation. 2024;149:e1165-75. https:\/\/doi.org\/10.1161\/CIR.0000000000001234.","journal-title":"Circulation"},{"key":"1149_CR34","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1038\/s41431-021-00838-5","volume":"29","author":"C Hoggart","year":"2021","unstructured":"Hoggart C, et al. Identification of novel locus associated with coronary artery aneurysms and validation of loci for susceptibility to Kawasaki disease. Eur J Hum Genet. 2021;29:1734\u201344. https:\/\/doi.org\/10.1038\/s41431-021-00838-5.","journal-title":"Eur J Hum Genet"},{"key":"1149_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41525-024-00419-7","author":"S Shrestha","year":"2024","unstructured":"Shrestha S, et al. Pharmacogenomics of coronary artery response to intravenous gamma globulin in Kawasaki disease. NPJ Genom Med. 2024. https:\/\/doi.org\/10.1038\/s41525-024-00419-7.","journal-title":"NPJ Genom Med"},{"key":"1149_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1284","volume":"10","author":"T Hara","year":"2021","unstructured":"Hara T, Yamamura K, Sakai Y. The up-to-date pathophysiology of Kawasaki disease. Clin Transl Immunol. 2021;10:e1284. https:\/\/doi.org\/10.1002\/cti2.1284.","journal-title":"Clin Transl Immunol"},{"key":"1149_CR37","doi-asserted-by":"publisher","first-page":"981010","DOI":"10.3389\/fcvm.2022.981010","volume":"9","author":"Y Qiu","year":"2022","unstructured":"Qiu Y, Zhang Y, Li Y, Hua Y, Zhang Y. Molecular mechanisms of endothelial dysfunction in Kawasaki-disease-associated vasculitis. Front Cardiovasc Med. 2022;9:981010. https:\/\/doi.org\/10.3389\/fcvm.2022.981010.","journal-title":"Front Cardiovasc Med"},{"key":"1149_CR38","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1203\/00006450-200101000-00017","volume":"49","author":"Y Hamamichi","year":"2001","unstructured":"Hamamichi Y, et al. Neutrophils and mononuclear cells express vascular endothelial growth factor in acute Kawasaki disease: its possible role in progression of coronary artery lesions. Pediatr Res. 2001;49:74\u201380. https:\/\/doi.org\/10.1203\/00006450-200101000-00017.","journal-title":"Pediatr Res"},{"key":"1149_CR39","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/j.1442-200X.2012.03609.x","volume":"54","author":"A McNeal-Davidson","year":"2012","unstructured":"McNeal-Davidson A, et al. Value of amino-terminal pro B-natriuretic peptide in diagnosing Kawasaki disease. Pediatr Int. 2012;54:627\u201333. https:\/\/doi.org\/10.1111\/j.1442-200X.2012.03609.x.","journal-title":"Pediatr Int"},{"key":"1149_CR40","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3345\/kjp.2016.59.12.477","volume":"59","author":"HY Lee","year":"2016","unstructured":"Lee HY, Song MS. Predictive factors of resistance to intravenous immunoglobulin and coronary artery lesions in Kawasaki disease. Korean J Pediatr. 2016;59:477\u201382. https:\/\/doi.org\/10.3345\/kjp.2016.59.12.477.","journal-title":"Korean J Pediatr"},{"key":"1149_CR41","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/jpc.12221","volume":"49","author":"D Yim","year":"2013","unstructured":"Yim D, Curtis N, Cheung M, Burgner D. An update on Kawasaki disease II: clinical features, diagnosis, treatment and outcomes. J Paediatr Child Health. 2013;49:614\u201323. https:\/\/doi.org\/10.1111\/jpc.12221.","journal-title":"J Paediatr Child Health"},{"key":"1149_CR42","doi-asserted-by":"publisher","first-page":"e927","DOI":"10.1161\/cir.0000000000000484","volume":"135","author":"BW McCrindle","year":"2017","unstructured":"McCrindle BW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135:e927-99. https:\/\/doi.org\/10.1161\/cir.0000000000000484.","journal-title":"Circulation"},{"key":"1149_CR43","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/ped.14326","volume":"62","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T, et al. Revision of diagnostic guidelines for Kawasaki disease (6th revised edition). Pediatr Int. 2020;62:1135\u20138. https:\/\/doi.org\/10.1111\/ped.14326.","journal-title":"Pediatr Int"},{"key":"1149_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2024.114145","volume":"274","author":"MD Elias","year":"2024","unstructured":"Elias MD, et al. Outcomes associated with giant coronary artery aneurysms after Kawasaki disease: a single-center united States experience. J Pediatr. 2024;274:114145. https:\/\/doi.org\/10.1016\/j.jpeds.2024.114145.","journal-title":"J Pediatr"},{"key":"1149_CR45","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1056\/NEJM199106063242305","volume":"324","author":"JW Newburger","year":"1991","unstructured":"Newburger JW, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633\u20139. https:\/\/doi.org\/10.1056\/NEJM199106063242305.","journal-title":"N Engl J Med"},{"key":"1149_CR46","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jpeds.2013.01.022","volume":"163","author":"T Kobayashi","year":"2013","unstructured":"Kobayashi T, et al. Efficacy of intravenous Immunoglobulin combined with prednisolone following resistance to initial intravenous Immunoglobulin treatment of acute Kawasaki disease. J Pediatr. 2013;163:521\u20136. https:\/\/doi.org\/10.1016\/j.jpeds.2013.01.022.","journal-title":"J Pediatr"},{"key":"1149_CR47","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S2352-4642(21)00270-4","volume":"5","author":"JC Burns","year":"2021","unstructured":"Burns JC, et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child Adolesc Health. 2021;5:852\u201361. https:\/\/doi.org\/10.1016\/S2352-4642(21)00270-4.","journal-title":"Lancet Child Adolesc Health"},{"key":"1149_CR48","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/art.41481","volume":"73","author":"I Kone-Paut","year":"2021","unstructured":"Kone-Paut I, et al. Phase II open label study of Anakinra in intravenous Immunoglobulin-resistant Kawasaki disease. Arthritis Rheumatol. 2021;73:151\u201361. https:\/\/doi.org\/10.1002\/art.41481.","journal-title":"Arthritis Rheumatol"},{"key":"1149_CR49","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1097\/INF.0b013e318220c3cf","volume":"30","author":"H Suzuki","year":"2011","unstructured":"Suzuki H, et al. Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr Infect Dis J. 2011;30:871\u20136. https:\/\/doi.org\/10.1097\/INF.0b013e318220c3cf.","journal-title":"Pediatr Infect Dis J"},{"key":"1149_CR50","doi-asserted-by":"publisher","first-page":"13856","DOI":"10.1038\/s41598-021-93459-3","volume":"11","author":"E Suganuma","year":"2021","unstructured":"Suganuma E, Sato S, Honda S, Nakazawa A. All trans retinoic acid alleviates coronary stenosis by regulating smooth muscle cell function in a mouse model of Kawasaki disease. Sci Rep. 2021;11:13856. https:\/\/doi.org\/10.1038\/s41598-021-93459-3.","journal-title":"Sci Rep"},{"key":"1149_CR51","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/art.42340","volume":"75","author":"AT Stock","year":"2023","unstructured":"Stock AT, et al. Mechanistic target of Rapamycin inhibition prevents coronary artery remodeling in a murine model of Kawasaki disease. Arthritis Rheumatol. 2023;75:305\u201317. https:\/\/doi.org\/10.1002\/art.42340.","journal-title":"Arthritis Rheumatol"},{"key":"1149_CR52","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1038\/s44319-024-00251-1","volume":"25","author":"AT Stock","year":"2024","unstructured":"Stock AT, et al. mTOR signalling controls the formation of smooth muscle cell-derived luminal myofibroblasts during vasculitis. EMBO Rep. 2024;25:4570\u201393. https:\/\/doi.org\/10.1038\/s44319-024-00251-1.","journal-title":"EMBO Rep"},{"key":"1149_CR53","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1007\/s00431-024-05765-3","volume":"183","author":"E Suganuma","year":"2024","unstructured":"Suganuma E, et al. Regression effect of renin-angiotensin-aldosterone system inhibitors on Kawasaki disease patients with coronary artery aneurysm: a prospective, observational study. Eur J Pediatr. 2024;183:4817\u201325. https:\/\/doi.org\/10.1007\/s00431-024-05765-3.","journal-title":"Eur J Pediatr"},{"key":"1149_CR54","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/art.1780370206","volume":"37","author":"JC Jennette","year":"1994","unstructured":"Jennette JC, et al. Nomenclature of systemic vasculitides. Arthritis Rheum. 1994;37:187\u201392. https:\/\/doi.org\/10.1002\/art.1780370206.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1149_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1\u201311. https:\/\/doi.org\/10.1002\/art.37715.","journal-title":"Arthritis Rheum"},{"key":"1149_CR56","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1055\/s-0038-1673386","volume":"39","author":"MA Alba","year":"2018","unstructured":"Alba MA, Jennette JC, Falk RJ. Pathogenesis of ANCA-associated pulmonary vasculitis. Semin Respir Crit Care Med. 2018;39:413\u201324. https:\/\/doi.org\/10.1055\/s-0038-1673386.","journal-title":"Semin Respir Crit Care Med"},{"issue":"1","key":"1149_CR57","doi-asserted-by":"publisher","first-page":"i104","DOI":"10.1093\/ndt\/gfv011","volume":"30","author":"AS Sacri","year":"2015","unstructured":"Sacri AS, et al. Clinical characteristics and outcomes of childhood-onset ANCA-associated vasculitis: a French nationwide study. Nephrol Dial Transpl. 2015;30(1):i104\u2013112. https:\/\/doi.org\/10.1093\/ndt\/gfv011.","journal-title":"Nephrol Dial Transpl"},{"key":"1149_CR58","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3899\/jrheum.090688","volume":"37","author":"S Grisaru","year":"2010","unstructured":"Grisaru S, Yuen GW, Miettunen PM, Hamiwka LA. Incidence of Wegener\u2019s granulomatosis in children. J Rheumatol. 2010;37:440\u20132. https:\/\/doi.org\/10.3899\/jrheum.090688.","journal-title":"J Rheumatol"},{"key":"1149_CR59","doi-asserted-by":"publisher","first-page":"iii42","DOI":"10.1093\/rheumatology\/keaa089","volume":"59","author":"AJ Mohammad","year":"2020","unstructured":"Mohammad AJ. An update on the epidemiology of ANCA-associated vasculitis. Rheumatology (Oxford). 2020;59:iii42\u201350. https:\/\/doi.org\/10.1093\/rheumatology\/keaa089.","journal-title":"Rheumatology (Oxford)"},{"key":"1149_CR60","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00467-019-04228-4","volume":"34","author":"D Hirano","year":"2019","unstructured":"Hirano D, et al. Epidemiology and clinical features of childhood-onset anti-neutrophil cytoplasmic antibody-associated vasculitis: a clinicopathological analysis. Pediatr Nephrol. 2019;34:1425\u201333. https:\/\/doi.org\/10.1007\/s00467-019-04228-4.","journal-title":"Pediatr Nephrol"},{"key":"1149_CR61","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/art.40112","volume":"69","author":"KA Morishita","year":"2017","unstructured":"Morishita KA, et al. Early outcomes in children with antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2017;69:1470\u20139. https:\/\/doi.org\/10.1002\/art.40112.","journal-title":"Arthritis Rheumatol"},{"key":"1149_CR62","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1002\/art.39729","volume":"68","author":"DA Cabral","year":"2016","unstructured":"Cabral DA, et al. Comparing presenting clinical features in 48 children with microscopic polyangiitis to 183 children who have granulomatosis with polyangiitis (Wegener\u2019s): an archive cohort study. Arthritis Rheumatol. 2016;68:2514\u201326. https:\/\/doi.org\/10.1002\/art.39729.","journal-title":"Arthritis Rheumatol"},{"key":"1149_CR63","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1182\/blood-2005-03-0921","volume":"106","author":"MA Little","year":"2005","unstructured":"Little MA, et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood. 2005;106:2050\u20138. https:\/\/doi.org\/10.1182\/blood-2005-03-0921.","journal-title":"Blood"},{"key":"1149_CR64","doi-asserted-by":"publisher","unstructured":"Xiao H et al. Injection of ANCA-No Neutrophils, No Glomerular Damage: The Role of Neutrophils in the Induction of Glomerulonephritis by Anti-Myeloperoxidase Antibodies. Am J Pathol 167: 39\u201345, 2005. J Am Soc Nephrol 16, 2521\u20132527. https:\/\/doi.org\/10.1681\/01.asn.0000926740.18373.6b (2005).","DOI":"10.1681\/01.asn.0000926740.18373.6b"},{"key":"1149_CR65","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3389\/fimmu.2016.00256","volume":"7","author":"D S\u00f6derberg","year":"2016","unstructured":"S\u00f6derberg D, Segelmark M. Neutrophil extracellular traps in ANCA-associated vasculitis. Front Immunol. 2016;7:256. https:\/\/doi.org\/10.3389\/fimmu.2016.00256.","journal-title":"Front Immunol"},{"key":"1149_CR66","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nm.1959","volume":"15","author":"K Kessenbrock","year":"2009","unstructured":"Kessenbrock K, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15:623\u20135. https:\/\/doi.org\/10.1038\/nm.1959.","journal-title":"Nat Med"},{"key":"1149_CR67","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1189\/jlb.0604319","volume":"76","author":"AP van Rossum","year":"2004","unstructured":"van Rossum AP, et al. Constitutive membrane expression of proteinase 3 (PR3) and neutrophil activation by anti-PR3 antibodies. J Leukoc Biol. 2004;76:1162\u201370. https:\/\/doi.org\/10.1189\/jlb.0604319.","journal-title":"J Leukoc Biol"},{"key":"1149_CR68","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1056\/NEJMoa1108735","volume":"367","author":"PA Lyons","year":"2012","unstructured":"Lyons PA, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367:214\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1108735.","journal-title":"N Engl J Med"},{"key":"1149_CR69","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1172\/jci65292","volume":"123","author":"AJ Roth","year":"2013","unstructured":"Roth AJ, et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest. 2013;123:1773\u201383. https:\/\/doi.org\/10.1172\/jci65292.","journal-title":"J Clin Invest"},{"key":"1149_CR70","doi-asserted-by":"publisher","first-page":"e0218272","DOI":"10.1371\/journal.pone.0218272","volume":"14","author":"S Ohlsson","year":"2019","unstructured":"Ohlsson S, et al. Neutrophils from ANCA-associated vasculitis patients show an increased capacity to activate the complement system via the alternative pathway after ANCA stimulation. PLoS ONE. 2019;14:e0218272. https:\/\/doi.org\/10.1371\/journal.pone.0218272.","journal-title":"PLoS ONE"},{"key":"1149_CR71","doi-asserted-by":"publisher","first-page":"SI122","DOI":"10.1093\/rheumatology\/kead693","volume":"63","author":"U Kaya Akca","year":"2024","unstructured":"Kaya Akca U, et al. Comparison of eular\/printo\/pres Ankara 2008 and 2022 ACR\/EULAR classification criteria for granulomatosis with polyangiitis in children. Rheumatology (Oxford). 2024;63:SI122. https:\/\/doi.org\/10.1093\/rheumatology\/kead693.","journal-title":"Rheumatology (Oxford)"},{"key":"1149_CR72","doi-asserted-by":"publisher","unstructured":"Toor KK et al. Evaluating Renal Disease in Pediatric-Onset Antineutrophil Cytoplasmic Antibody\u2013Associated Vasculitis: Disease Course, Outcomes, and Predictors of Outcome. Arthritis & Rheumatology n\/a. https:\/\/doi.org\/10.1002\/art.43071","DOI":"10.1002\/art.43071"},{"issue":"10","key":"1149_CR73","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.2215\/cjn.01210214","volume":"9","author":"DG Noone","year":"2014","unstructured":"Noone DG, et al. The new histopathologic classification of ANCA-associated GN and its association with renal outcomes in childhood. Clin J Am Soc Nephrol. 2014;9(10):1684\u201391. https:\/\/doi.org\/10.2215\/cjn.01210214.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1149_CR74","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3899\/jrheum.120808","volume":"40","author":"S Gendelman","year":"2013","unstructured":"Gendelman S, Zeft A, Spalding SJ. Childhood-onset eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): a contemporary single-center cohort. J Rheumatol. 2013;40:929\u201335. https:\/\/doi.org\/10.3899\/jrheum.120808.","journal-title":"J Rheumatol"},{"key":"1149_CR75","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/acr.24590","volume":"74","author":"KA Morishita","year":"2022","unstructured":"Morishita KA, et al. Consensus treatment plans for severe pediatric antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken). 2022;74:1550\u20138. https:\/\/doi.org\/10.1002\/acr.24590.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1149_CR76","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/acr.25455","volume":"77","author":"SJ Gagne","year":"2025","unstructured":"Gagne SJ, et al. Comparing rituximab and cyclophosphamide in induction therapy for childhood-onset anti-neutrophil cytoplasmic antibody-associated vasculitis: an archive registry cohort study. Arthritis Care Res (Hoboken). 2025;77:504\u201312. https:\/\/doi.org\/10.1002\/acr.25455.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1149_CR77","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung SA, et al. 2021 American college of rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic Antibody-Associated vasculitis. Arthritis Rheumatol. 2021;73:1366\u201383. https:\/\/doi.org\/10.1002\/art.41773.","journal-title":"Arthritis Rheumatol"},{"key":"1149_CR78","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","volume":"105","author":"KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody","year":"2024","unstructured":"KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody. (ANCA)-Associated vasculitis. Kidney Int. 2024;105:S71\u2013116. https:\/\/doi.org\/10.1016\/j.kint.2023.10.008.","journal-title":"Kidney Int"},{"key":"1149_CR79","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3899\/jrheum.200721","volume":"48","author":"A Mendel","year":"2021","unstructured":"Mendel A, et al. CanVasc consensus recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitis: 2020 update. J Rheumatol. 2021;48:555\u201366. https:\/\/doi.org\/10.3899\/jrheum.200721.","journal-title":"J Rheumatol"},{"key":"1149_CR80","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1093\/rheumatology\/kead087","volume":"62","author":"D Turgeon","year":"2023","unstructured":"Turgeon D, et al. CanVasc consensus recommendations for the use of Avacopan in antineutrophil cytoplasm antibody-associated vasculitis: 2022 addendum. Rheumatology (Oxford). 2023;62:2646\u201351. https:\/\/doi.org\/10.1093\/rheumatology\/kead087.","journal-title":"Rheumatology (Oxford)"},{"key":"1149_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-025-01080-9","author":"D Gezgin Yildirim","year":"2025","unstructured":"Gezgin Yildirim D, et al. Cyclophosphamide treatment with a comparison in both pediatric rheumatology and pediatric nephrology practices. Pediatr Rheumatol Online J. 2025. https:\/\/doi.org\/10.1186\/s12969-025-01080-9.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"Suppl 1","key":"1149_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-9-S1-P92","volume":"9","author":"P Dolezalova","year":"2011","unstructured":"Dolezalova P, et al. Disease activity in paediatric vasculitis: development of a generic assessment tool - PVAS. Pediatr Rheumatol Online J. 2011;9(Suppl 1):P92. https:\/\/doi.org\/10.1186\/1546-0096-9-S1-P92.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"Suppl 1","key":"1149_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-9-S1-O15","volume":"9","author":"FE Price-Kuehne","year":"2011","unstructured":"Price-Kuehne FE, et al. Preliminary validation of the paediatric vasculitis activity score (PVAS). Pediatr Rheumatol Online J. 2011;9(Suppl 1):O15. https:\/\/doi.org\/10.1186\/1546-0096-9-S1-O15.","journal-title":"Pediatr Rheumatol Online J"},{"key":"1149_CR84","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1093\/rheumatology\/keq167","volume":"49","author":"J Brunner","year":"2010","unstructured":"Brunner J, et al. Takayasu arteritis in children and adolescents. Rheumatology (Oxford). 2010;49:1806\u201314. https:\/\/doi.org\/10.1093\/rheumatology\/keq167.","journal-title":"Rheumatology (Oxford)"},{"key":"1149_CR85","doi-asserted-by":"publisher","first-page":"872313","DOI":"10.3389\/fped.2022.872313","volume":"10","author":"FA Aeschlimann","year":"2022","unstructured":"Aeschlimann FA, Yeung RSM, Laxer RM. An update on childhood-onset Takayasu arteritis. Front Pediatr. 2022;10:872313. https:\/\/doi.org\/10.3389\/fped.2022.872313.","journal-title":"Front Pediatr"},{"key":"1149_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103656","volume":"23","author":"R Terribili","year":"2024","unstructured":"Terribili R, Conticini E, Grazzini S, Cantarini L, Frediani B. Impact of non-immunosuppressive medical therapy on disease progression and complications of Takayasu arteritis: a narrative review. Autoimmun Rev. 2024;23:103656. https:\/\/doi.org\/10.1016\/j.autrev.2024.103656.","journal-title":"Autoimmun Rev"},{"key":"1149_CR87","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/j.lpm.2016.11.031","volume":"46","author":"P Renauer","year":"2017","unstructured":"Renauer P, Sawalha AH. The genetics of Takayasu arteritis. Presse Med. 2017;46:e179\u201387. https:\/\/doi.org\/10.1016\/j.lpm.2016.11.031.","journal-title":"Presse Med"},{"key":"1149_CR88","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41572-021-00327-5","volume":"7","author":"D Pugh","year":"2022","unstructured":"Pugh D, et al. Large-vessel vasculitis. Nat Rev Dis Primers. 2022;7:93. https:\/\/doi.org\/10.1038\/s41572-021-00327-5.","journal-title":"Nat Rev Dis Primers"},{"key":"1149_CR89","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1146\/annurev-med-060622-100940","volume":"75","author":"MS Kaymakci","year":"2024","unstructured":"Kaymakci MS, Warrington KJ, Kermani TA. New therapeutic approaches to large-vessel vasculitis. Annu Rev Med. 2024;75:427\u201342. https:\/\/doi.org\/10.1146\/annurev-med-060622-100940.","journal-title":"Annu Rev Med"},{"key":"1149_CR90","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/annrheumdis-2019-216900","volume":"79","author":"P R\u00e9gnier","year":"2020","unstructured":"R\u00e9gnier P, et al. Targeting JAK\/STAT pathway in takayasu\u2019s arteritis. Ann Rheum Dis. 2020;79:951\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216900.","journal-title":"Ann Rheum Dis"},{"key":"1149_CR91","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1161\/circulationaha.110.936203","volume":"123","author":"K Piggott","year":"2011","unstructured":"Piggott K, et al. Blocking the NOTCH pathway inhibits vascular inflammation in large-vessel vasculitis. Circulation. 2011;123:309\u201318. https:\/\/doi.org\/10.1161\/circulationaha.110.936203.","journal-title":"Circulation"},{"key":"1149_CR92","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/art.42103","volume":"74","author":"W Jiang","year":"2022","unstructured":"Jiang W, et al. Critical role of Notch-1 in mechanistic target of Rapamycin hyperactivity and vascular inflammation in patients with Takayasu arteritis. Arthritis Rheumatol. 2022;74:1235\u201344. https:\/\/doi.org\/10.1002\/art.42103.","journal-title":"Arthritis Rheumatol"},{"key":"1149_CR93","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11926-020-00948-x","volume":"22","author":"R Watanabe","year":"2020","unstructured":"Watanabe R, Berry GJ, Liang DH, Goronzy JJ, Weyand CM. Pathogenesis of giant cell arteritis and Takayasu arteritis-similarities and differences. Curr Rheumatol Rep. 2020;22:68. https:\/\/doi.org\/10.1007\/s11926-020-00948-x.","journal-title":"Curr Rheumatol Rep"},{"key":"1149_CR94","doi-asserted-by":"publisher","unstructured":"Grayson PC et al. 2022 American College of Rheumatology\/EULAR Classification Criteria for Takayasu Arteritis. Arthritis Rheumatol 74, 1872\u20131880. https:\/\/doi.org\/10.1002\/art.42324 (2022).","DOI":"10.1002\/art.42324"},{"key":"1149_CR95","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13075-017-1452-4","volume":"19","author":"FA Aeschlimann","year":"2017","unstructured":"Aeschlimann FA, et al. Childhood Takayasu arteritis: disease course and response to therapy. Arthritis Res Ther. 2017;19:255. https:\/\/doi.org\/10.1186\/s13075-017-1452-4.","journal-title":"Arthritis Res Ther"},{"key":"1149_CR96","doi-asserted-by":"publisher","first-page":"517","DOI":"10.5152\/TurkArchPediatr.2024.24181","volume":"59","author":"Y Bay\u0131nd\u0131r","year":"2024","unstructured":"Bay\u0131nd\u0131r Y, Ba\u015faran \u00d6, Bilginer Y, \u00d6zen S. Vasculitis in children. Turk Arch Pediatr. 2024;59:517\u201326. https:\/\/doi.org\/10.5152\/TurkArchPediatr.2024.24181.","journal-title":"Turk Arch Pediatr"},{"key":"1149_CR97","doi-asserted-by":"publisher","first-page":"32","DOI":"10.55563\/clinexprheumatol\/kr357t","volume":"39","author":"EC Bolek","year":"2021","unstructured":"Bolek EC, et al. Is takayasu\u2019s arteritis more severe in children? Clin Exp Rheumatol. 2021;39:32\u20138. https:\/\/doi.org\/10.55563\/clinexprheumatol\/kr357t.","journal-title":"Clin Exp Rheumatol"},{"key":"1149_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2021.101008","volume":"47","author":"MB Torres-Rojas","year":"2022","unstructured":"Torres-Rojas MB, et al. Takayasu\u2019s arteritis as a rare cause of group 4 pulmonary hypertension. Curr Probl Cardiol. 2022;47:101008. https:\/\/doi.org\/10.1016\/j.cpcardiol.2021.101008.","journal-title":"Curr Probl Cardiol"},{"key":"1149_CR99","doi-asserted-by":"publisher","first-page":"637","DOI":"10.4103\/ijo.Ijo_1346_23","volume":"72","author":"U Sharma","year":"2024","unstructured":"Sharma U, Rishi E, Rishi P, Gupta V, Raman R. Posterior segment manifestations of Takayasu arteritis: A narrative review. Indian J Ophthalmol. 2024;72:637\u201347. https:\/\/doi.org\/10.4103\/ijo.Ijo_1346_23.","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"1149_CR100","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/art.42290","volume":"75","author":"KA Quinn","year":"2023","unstructured":"Quinn KA, et al. Association of (18)F-fluorodeoxyglucose-positron emission tomography activity with angiographic progression of disease in large vessel vasculitis. Arthritis Rheumatol. 2023;75(1):98\u2013107. https:\/\/doi.org\/10.1002\/art.42290.","journal-title":"Arthritis Rheumatol"},{"key":"1149_CR101","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/1754-9485.13800","volume":"68","author":"KB Singh","year":"2024","unstructured":"Singh KB, Nguyen K, Sammel A, Wegner EA. Ho shon, I. FDG PET\/CT in large vessel vasculitis. J Med Imaging Radiat Oncol. 2024;68:881\u201392. https:\/\/doi.org\/10.1111\/1754-9485.13800.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"1149_CR102","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1136\/ard-2023-224543","volume":"83","author":"C Dejaco","year":"2024","unstructured":"Dejaco C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. Ann Rheum Dis. 2024;83:741\u201351. https:\/\/doi.org\/10.1136\/ard-2023-224543.","journal-title":"Ann Rheum Dis"},{"key":"1149_CR103","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11926-021-01032-8","volume":"23","author":"S Sener","year":"2021","unstructured":"Sener S, Basaran O, Ozen S. Wind of change in the treatment of Childhood-Onset Takayasu arteritis: a systematic review. Curr Rheumatol Rep. 2021;23:68. https:\/\/doi.org\/10.1007\/s11926-021-01032-8.","journal-title":"Curr Rheumatol Rep"},{"key":"1149_CR104","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1253\/circj.CJ-23-0780","volume":"88","author":"Y Arita","year":"2024","unstructured":"Arita Y, Ishibashi T, Nakaoka Y. Current immunosuppressive treatment for Takayasu arteritis. Circ J. 2024;88:1605\u20139. https:\/\/doi.org\/10.1253\/circj.CJ-23-0780.","journal-title":"Circ J"},{"key":"1149_CR105","doi-asserted-by":"publisher","first-page":"881705","DOI":"10.3389\/fimmu.2022.881705","volume":"13","author":"R Watanabe","year":"2022","unstructured":"Watanabe R, Hashimoto M. Perspectives of JAK inhibitors for large vessel vasculitis. Front Immunol. 2022;13:881705. https:\/\/doi.org\/10.3389\/fimmu.2022.881705.","journal-title":"Front Immunol"},{"key":"1149_CR106","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.semarthrit.2018.04.004","volume":"48","author":"R Conway","year":"2018","unstructured":"Conway R, et al. Ustekinumab for refractory giant cell arteritis: a prospective 52-week trial. Semin Arthritis Rheum. 2018;48:523\u20138. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.04.004.","journal-title":"Semin Arthritis Rheum"},{"key":"1149_CR107","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.berh.2018.07.006","volume":"32","author":"L Guillevin","year":"2018","unstructured":"Guillevin L, Mukhtyar C, Pagnoux C, Yates M. Conventional and biological immunosuppressants in vasculitis. Best Pract Res Clin Rheumatol. 2018;32:94\u2013111. https:\/\/doi.org\/10.1016\/j.berh.2018.07.006.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1149_CR108","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1093\/rheumatology\/kex493","volume":"57","author":"D Nakagomi","year":"2018","unstructured":"Nakagomi D, Kronbichler A, Witte T, Mohammad AJ, Jayne DRW. Comment on: rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. Rheumatology (Oxford). 2018;57:1309\u201310. https:\/\/doi.org\/10.1093\/rheumatology\/kex493.","journal-title":"Rheumatology (Oxford)"},{"key":"1149_CR109","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1161\/circulationaha.111.058032","volume":"125","author":"D Saadoun","year":"2012","unstructured":"Saadoun D, et al. Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience. Circulation. 2012;125:813\u20139. https:\/\/doi.org\/10.1161\/circulationaha.111.058032.","journal-title":"Circulation"},{"key":"1149_CR110","unstructured":"Friese JL et al. Springer Berlin Heidelberg,. in Systemic Vasculitis: Imaging Features (eds Lotfi Hendaoui, Anthony W. Stanson, M. Habib Bouhaouala, & Francis Joffre) 189\u2013207 (2012)."},{"key":"1149_CR111","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.pcl.2012.03.013","volume":"59","author":"PF Weiss","year":"2012","unstructured":"Weiss PF. Pediatric vasculitis. Pediatr Clin North Am. 2012;59:407\u201323. https:\/\/doi.org\/10.1016\/j.pcl.2012.03.013.","journal-title":"Pediatr Clin North Am"},{"key":"1149_CR112","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/art.42817","volume":"76","author":"O Karadag","year":"2024","unstructured":"Karadag O, et al. Clinical characteristics and outcomes of polyarteritis nodosa: an international study. Arthritis Rheumatol. 2024;76:1120\u20139. https:\/\/doi.org\/10.1002\/art.42817.","journal-title":"Arthritis Rheumatol"},{"issue":"sup1","key":"1149_CR113","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/00325481.2022.2088940","volume":"135","author":"JM Springer","year":"2023","unstructured":"Springer JM, Byram K. Polyarteritis nodosa: an evolving primary systemic vasculitis. Postgrad Med. 2023;135(sup1):61\u20138. https:\/\/doi.org\/10.1080\/00325481.2022.2088940.","journal-title":"Postgrad Med"},{"key":"1149_CR114","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s00296-018-4122-1","volume":"38","author":"O Karadag","year":"2018","unstructured":"Karadag O, et al. A retrospective study comparing the phenotype and outcomes of patients with polyarteritis nodosa between UK and Turkish cohorts. Rheumatol Int. 2018;38:1833\u201340. https:\/\/doi.org\/10.1007\/s00296-018-4122-1.","journal-title":"Rheumatol Int"},{"key":"1149_CR115","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/acr.24633","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung SA, et al. 2021 American college of rheumatology\/vasculitis foundation guideline for the management of polyarteritis nodosa. Arthritis Care Res (Hoboken). 2021;73:1061\u201370. https:\/\/doi.org\/10.1002\/acr.24633.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1149_CR116","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/mop.0000000000001106","volume":"34","author":"Y Bilginer","year":"2022","unstructured":"Bilginer Y, Ozen S. Polyarteritis nodosa. Curr Opin Pediatr. 2022;34:229\u201333. https:\/\/doi.org\/10.1097\/mop.0000000000001106.","journal-title":"Curr Opin Pediatr"},{"key":"1149_CR117","doi-asserted-by":"publisher","first-page":"e2315894","DOI":"10.1001\/jamanetworkopen.2023.15894","volume":"6","author":"PY Lee","year":"2023","unstructured":"Lee PY, et al. Evaluation and management of deficiency of adenosine deaminase 2: an international consensus statement. JAMA Netw Open. 2023;6:e2315894. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.15894.","journal-title":"JAMA Netw Open"},{"key":"1149_CR118","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3899\/jrheum.181384","volume":"47","author":"S \u00d6zen","year":"2020","unstructured":"\u00d6zen S, et al. A monogenic disease with a variety of phenotypes: deficiency of adenosine deaminase 2. J Rheumatol. 2020;47:117\u201325. https:\/\/doi.org\/10.3899\/jrheum.181384.","journal-title":"J Rheumatol"},{"key":"1149_CR119","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1002\/art.40913","volume":"71","author":"KM Gibson","year":"2019","unstructured":"Gibson KM, et al. Identification of novel adenosine deaminase 2 gene variants and varied clinical phenotype in pediatric vasculitis. Arthritis Rheumatol. 2019;71:1747\u201355. https:\/\/doi.org\/10.1002\/art.40913.","journal-title":"Arthritis Rheumatol"},{"key":"1149_CR120","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1136\/annrheumdis-2016-210802","volume":"76","author":"R Caorsi","year":"2017","unstructured":"Caorsi R, et al. ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. Ann Rheum Dis. 2017;76:1648\u201356. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210802.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1149_CR121","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.autrev.2016.02.015","volume":"15","author":"A De Virgilio","year":"2016","unstructured":"De Virgilio A, et al. Polyarteritis nodosa: a contemporary overview. Autoimmun Rev. 2016;15(6):564\u201370. https:\/\/doi.org\/10.1016\/j.autrev.2016.02.015.","journal-title":"Autoimmun Rev"},{"key":"1149_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.129658","volume":"261","author":"X Tang","year":"2024","unstructured":"Tang X, Guo J, Qi F, Rezaei MJ. Role of non-coding RNAs and exosomal non-coding RNAs in vasculitis: a narrative review. Int J Biol Macromol. 2024;261:129658. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.129658.","journal-title":"Int J Biol Macromol"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01149-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-025-01149-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01149-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T12:47:27Z","timestamp":1759754847000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-025-01149-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":122,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1149"],"URL":"https:\/\/doi.org\/10.1186\/s12969-025-01149-5","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate declarations"}},{"value":"declaration\n                      : Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}